摘要
目的:观察阿维A联合血管扩张剂治疗系统性硬皮病(SSc)的疗效和安全性。方法:收集2000—2005年住院和门诊就诊的6例SSc患者,主要使用阿维A0.5~0.6mg/(kg·d)和扩张血管药物等治疗。皮肤受累程度采用改良的Rodnan评分法评估,治疗后评分减少75%以上为临床显效。结果:6例患者中有5例伴有关节疼和雷诺征(83.33%),另1例伴有吞咽困难(16.67%),均无其他内脏受累;治疗前皮肤硬化程度评分平均为(22.00±6.96)分(12~30分)。治疗2周后,所有患者的关节疼、雷诺征及吞咽困难逐渐缓解,部分患者面部等处皮肤开始变软;8周后,所有患者的皮肤症状改善,皮肤硬化程度平均评分下降至(7.17±3.92)分(2~12分),与治疗前比较差异有统计学意义(P<0.05)。4例患者疗效显著,2例患者在治疗2周后出现肝功能异常、血脂升高。结论:阿维A联合血管扩张剂治疗SSc有效。
Objective: To observe the efficacy of acitretin in combination with vasodilators in the treatment of systemic sclerosis(SSc). Methods: Six in-patients and out-patients with SSc from 2000 to 2005 were analyzed. All patients were treated with acitretin 0.5-0.6 mg/(kg·d) in combination with vasodilators. Skin thickness and hardness were assessed by using the modified Rodnan score, of which reduction of more than 75% was defined as significant improvement. Results: In 6 SSc patients, 5 (83.33%) of them were accompanied by arthralgia and Raynaud's phenomenon, 1 case (16.67%) with dysphasia, no symptoms and signs suggesting other internal organs involved. Rodnan score ranged from 12 to 30(22.00±6.96) before treatment. After the combination therapy, all the clinical symptoms and signs of the patients improved. The Rodnan score decreased after 2 weeks, and continued to decrease. By the end of the 8th week, the Rodnan score was 2-12(7.17±3.92), which showed statistical difference compared with that of the pre-treatment(P 〈 0.05). Four cases showed marked improvement, while 2 cases developed abnormal liver function and hyperlipidemia, which had no influence on the continuation of therapy. Conclusion: The preliminary study suggests that acitretin in combination with vasodilators be the choice of treatment for SSc.
出处
《临床皮肤科杂志》
CAS
CSCD
北大核心
2007年第2期113-114,共2页
Journal of Clinical Dermatology